MeFAMP for Imaging System a Amino Acid Transport in Primary and Metastatic Brain Tumors

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 30, 2025

Primary Completion Date

August 30, 2027

Study Completion Date

August 30, 2027

Conditions
Healthy VolunteersRecurrent GliomaBrain Metastases from Extra-cranial Solid Tumors
Interventions
DRUG

[F-18]MeFAMP PET

Study participants will receive the fluorine-18 labeled system A amino acid transport substrate, (R)-3-\[F-18\]fluoro-2-methyl-2-(methylamino)propanoic acid (\[F-18\]MeFAMP), for positron emission tomography (PET). Participants in Cohorts 1 and 2 will receive a single administration of the study drug. Participants in cohort 3 will receive 2 administrations of the study drug, once before standard of care radiation therapy for brain metastases and once after.

Trial Locations (1)

35294

UAB, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER

NCT05676489 - MeFAMP for Imaging System a Amino Acid Transport in Primary and Metastatic Brain Tumors | Biotech Hunter | Biotech Hunter